Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
INTRODUCTION
Sézary syndrome (SS) is a rare entity constituting less than 5% of all primary cutaneous T-cell lymphomas (CTCLs). Its description is a clinical triad composed of erythroderma, generalized lymphadenopathy, and the presence of Sézary cells in peripheral blood. There is insufficient information to establish a prognostic index for Sézary syndrome, although it is known that the high count of Sézary cells, loss of T-cell markers and chromosomal alterations in circulating T lymphocytes are independently associated with poor prognosis. 1, 2 It is a difficult-to-treat entity, which often becomes refractory to chemotherapy agents. We report the case of a patient with SS, with a favourable and maintained response to alemtuzumab.
CASE REPORT
A 70-year-old male, with hypertension and chronic obstructive pulmonary disease, and no other relevant history, was referred from another centre due to 2 years of erythroderma with intense pruritus. He was refractory to topical and oral corticosteroid therapy. On examination, the patient presented a shiny, bright 
DISCUSSION
SS is a poor prognostic pCTCL, which can be refractory to the multiple regimens used in over 75% of cases. 3 The emergence of new molecular targets has allowed the use of drugs such as alemtuzumab, which has provided promising results in Phase 2 clinical trials and observational studies. but not by hematopoietic stem cells. 3 It induces a blood depletion of these cell groups through antibody-dependent cytotoxicity, complement activation and apoptosis. 2, 4 Initially approved for use in chronic lymphocytic leukaemia, its subsequent approval for multiple sclerosis has prompted its market withdrawal for hematologic use due to economic reasons. 6 Despite being classified as an orphan drug by the EMA, this drug can still be used off-label. The elevated CD52 expression on the CD4 + T lymphocytes, the main circulating cell in the SS, has motivated the use of alemtuzumab in mycosis fungoides (MF) and SS. 3, 7 Its efficacy is higher in patients with erythroderma, intense pruritus and those who have not received prior treatment 4, 7 , with response rates ranging from 70-86% of cases. 2, 4, 7 Masson et al. observed a 70% overall response rate in patients with SS after a median follow-up of 24 months. This response was sustained for 6 to 56 months in the different series. 5, 7 However, the main limitation to the use of alemtuzumab is its adverse effects, particularly haematological toxicity (grade 4 cytopenias) and infectious complications (reactivation of CMV, Pneumocystis jirovecii infections and fungal sepsis). 3, 7 In addition, post-infusion reactions may occur with fever, nausea, hypotension, rash/urticaria and fatigue, which are generally limited to the initial doses of therapy and can be minimized with corticosteroid therapy. 4 This high toxicity leads to the withdrawal of medication in 44% of cases, with a mortality rate of up to 5% that can be attributed to the drug. 7 Although the standard dose of alemtuzumab is 30mg/3 times a week in most studies, dosage regimens with lower doses 
